Assessing Future Treatment Options for Patients With Resectable Non-Small Cell Lung Cancer
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what the findings of the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer may mean for future treatment options.
Pharmacy Times interviewed Jonathan Spicer, MD, associate professor of surgery at McGill University and medical director of the McGill University Health Center Thoracic Oncology Network, on his presentation at the 2021 American Society of Clinical Oncology Annual Meeting on surgical outcomes from the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer.
During the discussion, Spicer addresses what the findings of the phase 3 trial may mean for patients who are currently undergoing chemotherapy, as well as in terms of their future treatment options.
